File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and E-test

TitleSusceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and E-test
Authors
Issue Date1999
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/diagmicrobio
Citation
Diagnostic Microbiology and Infectious Disease, 1999, v. 34 n. 1, p. 1-6 How to Cite?
AbstractA prospective study on the susceptibility of Clostridium difficile to metronidazole and vancomycin using the Etest and disk diffusion test was performed over a 6-month period. One hundred strains were tested; one strain was highly resistant to metronidazole (MIC = 64 μg/mL). The zone size of inhibition by the disk diffusion test correlated with the MIC as determined by the Etest (regression coefficient = -0.043 for metronidazole and -0.044 for vancomycin, p < 0.001 for both antibiotics). However, the correlation coefficient was low for both metronidazole (r = 0.574) and vancomycin (r = 0.473); hence the zone of inhibition by disk diffusion test could not predict the MIC satisfactorily. Metronidazole is still the first-line antibiotic for the treatment of C. difficile-associated diarrhea because the incidence of metronidazole resistant strains remains very low. However, the efficacy of metronidazole in the treatment of infections attributable to isolates with high-level metronidazole resistance may be compromised because the fecal concentration of metronidazole is relatively low when compared with the MIC values of the less susceptible strains. Oral vancomycin is the drug of choice under such circumstances, as its fecal concentration is much higher than that of metronidazole. Copyright (C) 1999 Elsevier Science Inc.
Persistent Identifierhttp://hdl.handle.net/10722/157296
ISSN
2015 Impact Factor: 2.45
2015 SCImago Journal Rankings: 1.142
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, SSYen_US
dc.contributor.authorWoo, PCYen_US
dc.contributor.authorLuk, WKen_US
dc.contributor.authorYuen, KYen_US
dc.date.accessioned2012-08-08T08:48:44Z-
dc.date.available2012-08-08T08:48:44Z-
dc.date.issued1999en_US
dc.identifier.citationDiagnostic Microbiology and Infectious Disease, 1999, v. 34 n. 1, p. 1-6en_US
dc.identifier.issn0732-8893en_US
dc.identifier.urihttp://hdl.handle.net/10722/157296-
dc.description.abstractA prospective study on the susceptibility of Clostridium difficile to metronidazole and vancomycin using the Etest and disk diffusion test was performed over a 6-month period. One hundred strains were tested; one strain was highly resistant to metronidazole (MIC = 64 μg/mL). The zone size of inhibition by the disk diffusion test correlated with the MIC as determined by the Etest (regression coefficient = -0.043 for metronidazole and -0.044 for vancomycin, p < 0.001 for both antibiotics). However, the correlation coefficient was low for both metronidazole (r = 0.574) and vancomycin (r = 0.473); hence the zone of inhibition by disk diffusion test could not predict the MIC satisfactorily. Metronidazole is still the first-line antibiotic for the treatment of C. difficile-associated diarrhea because the incidence of metronidazole resistant strains remains very low. However, the efficacy of metronidazole in the treatment of infections attributable to isolates with high-level metronidazole resistance may be compromised because the fecal concentration of metronidazole is relatively low when compared with the MIC values of the less susceptible strains. Oral vancomycin is the drug of choice under such circumstances, as its fecal concentration is much higher than that of metronidazole. Copyright (C) 1999 Elsevier Science Inc.en_US
dc.languageengen_US
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/diagmicrobioen_US
dc.relation.ispartofDiagnostic Microbiology and Infectious Diseaseen_US
dc.rightsDiagnostic Microbiology and Infectious Disease. Copyright © Elsevier Inc.-
dc.subject.meshAnti-Bacterial Agents - Pharmacologyen_US
dc.subject.meshClostridium Difficile - Drug Effects - Growth & Developmenten_US
dc.subject.meshDiarrhea - Microbiologyen_US
dc.subject.meshDrug Resistance, Microbialen_US
dc.subject.meshEnterocolitis, Pseudomembranous - Microbiologyen_US
dc.subject.meshHumansen_US
dc.subject.meshMetronidazole - Pharmacologyen_US
dc.subject.meshMicrobial Sensitivity Tests - Methodsen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshVancomycin - Pharmacologyen_US
dc.titleSusceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and E-testen_US
dc.typeArticleen_US
dc.identifier.emailWong, SSY: samsonsy@hkucc.hku.hken_US
dc.identifier.emailWoo, PCY: pcywoo@hkucc.hku.hken_US
dc.identifier.emailYuen, KY: kyyuen@hkucc.hku.hken_US
dc.identifier.authorityWong, SSY=rp00395en_US
dc.identifier.authorityWoo, PCY=rp00430en_US
dc.identifier.authorityYuen, KY=rp00366en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/S0732-8893(98)00139-4en_US
dc.identifier.pmid10342100-
dc.identifier.scopuseid_2-s2.0-0032939481en_US
dc.identifier.hkuros46198-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0032939481&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume34en_US
dc.identifier.issue1en_US
dc.identifier.spage1en_US
dc.identifier.epage6en_US
dc.identifier.isiWOS:000080305100001-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridWong, SSY=13310021400en_US
dc.identifier.scopusauthoridWoo, PCY=7201801340en_US
dc.identifier.scopusauthoridLuk, WK=7005237832en_US
dc.identifier.scopusauthoridYuen, KY=36078079100en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats